HII to Strengthen Nuclear-Powered Submarine Supply Chain
The contract's initial value is $9.6 million (AUD) with the option to extend based on achievement.
The pilot program will support the development of a sovereign robust, internationally integrated supply chain, accelerating Australian industry's critical contribution to the success of the AUKUS trilateral security partnership between Australia, the United Kingdom, and the United States.
'This contract represents a significant milestone in building a resilient and globally integrated supply chain for nuclear-powered submarines,' said Chris Kastner, president and CEO of HII. 'HII has a long history of working with suppliers to ensure they meet the highest standards in safety, security, and performance. We welcome Australian partners to help build out this critical nuclear shipbuilding capability and ensure the long-term success of AUKUS.'
A photo accompanying this release is available at: http://hii.com/news/hii-to-strengthen-nuclear-powered-submarine-supply-chain/.
The HII led AUSSQ pilot program is part of the Australian Government's comprehensive 'AUKUS Submarine Industry Strategy,' released by the Australian Submarine Agency on March 5, 2025. The Industry Strategy 'identifies the conditions to develop the sovereign industrial capability needed to deliver, operate and sustain our future conventionally-armed, nuclear-powered submarines, while also ensuring our existing Collins -class submarines are sustained and upgraded until their eventual withdrawal from service.'
The AUKUS Submarine Industry Strategy states, 'The [AUSSQ Pilot program] will use a B2B model, enabling HII Australia to work directly with Australian businesses to qualify both the businesses and their products, and subsequently assist them to tender for supply into the US programs.'
'An Australian submarine industrial base capable of building and sustaining a persistent, potent and sovereign multi-class submarine capability is vital to the defense of Australia, and this Pilot initiative with HII Australia is another important step to this being achieved,' stated Richard Marles, deputy prime minister of Australia and Australia minister for Defence.
The AUSSQ pilot program will engage with Australian companies nationwide, building on the success of the recent partnership of HII Australia with both the South Australian Government and the Western Australian government, and complements the Australian government's existing Defence Industry Vendor Qualification (DIVQ) Program.
With over 60 years of experience managing complex supplier networks for U.S. Navy nuclear-powered submarine programs and maintaining a strong nuclear stewardship culture for the U.S. Department of Energy (DOE) on critical national security projects, HII's expertise in quality assurance, safety, and technical training will support Australian industry in meeting the stringent requirements for nuclear-powered submarine construction. The company also brings a record of advancing science, technology, and environmental protection, as well as proven performance in developing and sustaining a highly skilled nuclear workforce, including by investing in education and training programs that attract, develop, and retain top talent in local communities. By leveraging this extensive experience, HII is prepared to support Australia's efforts to build and sustain a robust industrial base capable of supporting these highly sophisticated vessels.
Every year HII spends approximately $1 billion with more than 2,000 suppliers in the United States, with nearly half of this amount going to small businesses.
HII's engagement will focus on assessing and developing Australian suppliers, providing technical guidance, and implementing best practices to ensure compliance with the precise specifications required for nuclear submarine components. By leveraging HII's deep experience in supply chain management and industrial base expansion, the program aims to establish a sustainable pipeline of qualified suppliers, reinforcing the broader AUKUS effort. This contract works in conjunction with our Global Supply Chain Program's broader Australian supplier initiatives.
The contract will be managed by HII's Australian operations leveraging the company's local and international strengths and skills delivered, and in partnership with H&B Defence – a HII and Babcock joint venture.
For more information about HII's role in nuclear-powered shipbuilding and supplier development, visit https://hii.com/what-we-do/sectors/hii-australia.
About HII
HII is a global, all-domain defense provider. HII's mission is to deliver the world's most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world.
As the nation's largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII's workforce is 44,000 strong. For more information, visit:
Contact:
Greg McCarthy
(202) 264-7126
gregory.j.mccarthy@hii-co.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Cybin Announces Results of Annual Meeting of Shareholders
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the ' Meeting '). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: 1. Appointment of Auditor Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below: Votes For Votes Withheld # % # % 11,206,201 99.485 58,010 0.515% 2. Number of Directors The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below: Votes For Votes Against # % # % 10,470,055 92.950 794,156 7.050 3. Election of Directors Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below: Votes For Votes Withheld # % # % Theresa Firestone 4,786,111 86.161 768,746 13.839 Grant Froese 4,787,135 86.179 767,722 13.821 Paul Glavine 4,789,854 86.228 765,004 13.772 Eric Hoskins 3,406,590 61.326 2,148,267 38.674 Mark Lawson 4,788,272 86.200 766,585 13.800 Eric So 4,779,295 86.038 775,563 13.962 George Tziras did not stand for re-election as a director. The Company thanks Mr. Tziras for his past service. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Globe and Mail
9 hours ago
- Globe and Mail
Dell Technologies to Hold Conference Call Aug. 28 to Discuss Second Quarter Fiscal 2026 Financial Results
Dell Technologies (NYSE: DELL) will conduct a conference call Thursday, Aug. 28, 2025, at 3:30 p.m. CST to discuss its fiscal 2026 second quarter financial results. The conference will be available to the public as a live, audio-only webcast on Dell Technologies' website at an archived version will be available at the same location. The company will issue the results before the conference call broadcast via a press release with accompanying financial statements and guidance. At that time, the release, prepared remarks and a presentation containing additional financial and operating information with financial guidance may be downloaded from Dell Technologies Dell Technologies (NYSE:DELL) helps organizations and individuals build their digital future and transform how they work, live and play. The company provides customers with the industry's broadest and most innovative technology and services portfolio for the AI era. Copyright © 2025 Dell Inc. or its subsidiaries. All Rights Reserved. Dell Technologies, Dell, EMC, Dell EMC and other trademarks are trademarks of Dell Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
Globe and Mail
9 hours ago
- Globe and Mail
Essential Properties Realty Trust, Inc. Announces Pricing of $400 Million of 5.400% Senior Notes due 2035
Essential Properties Realty Trust, Inc. (NYSE: EPRT; the 'Company') announced today that its operating partnership, Essential Properties, L.P. (the 'Operating Partnership'), has priced a public offering of $400 million aggregate principal amount of 5.400% Senior Notes due 2035 (the 'Notes'). The Notes were priced at 98.317% of the principal amount and will mature on December 1, 2035. The offering is expected to settle on August 21, 2025, subject to the satisfaction of customary closing conditions. The Notes will be fully and unconditionally guaranteed by the Company. The Operating Partnership intends to use the net proceeds from the offering (i) to repay amounts outstanding under its revolving credit facility and (ii) for general corporate purposes, including funding future investment activity. Wells Fargo Securities, Mizuho, BMO Capital Markets, BofA Securities, Capital One Securities, TD Securities and Truist Securities are acting as joint book-running managers for the offering. Barclays, BNP PARIBAS, Citigroup, Citizens Capital Markets, Goldman Sachs & Co. LLC, Huntington Capital Markets, Morgan Stanley, Regions Securities LLC, Scotiabank, Stifel and Wolfe Capital Markets and Advisory are acting as co-managers for the offering. The offering is being made pursuant to an effective shelf registration statement filed by the Company and the Operating Partnership with the Securities and Exchange Commission (the 'SEC'). A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, a copy of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attention: WFS Customer Service, toll-free at 1-800-645-3751; or Mizuho Securities USA LLC, Attention: Debt Capital Markets, 1271 Avenue of the Americas, New York, NY 10020, at 1-866-271-7403, or by visiting the EDGAR database on the SEC's web site at This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. When used in this press release, the words 'expect' and 'will,' or the negative of these words, or similar words or phrases that are predictions of or indicate future events and that do not relate solely to historical matters, are intended to identify forward-looking statements. You can also identify forward-looking statements by discussions regarding strategy, plans or intentions. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise. The Company does not guarantee that the transactions and events described will happen as described (or that they will happen at all). You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. While forward-looking statements reflect the Company's good faith beliefs, they are not guarantees of future performance. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. In light of these risks and uncertainties, the forward-looking events discussed in this press release might not occur as described, or at all. Additional information concerning factors that could cause actual results to differ materially from these forward-looking statements is contained from time to time in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. Copies of each filing may be obtained from the Company or the SEC. Such forward-looking statements should be regarded solely as reflections of the Company's current plans and estimates. Actual results may differ materially from what is expressed or forecast in this press release. About Essential Properties Realty Trust, Inc. Essential Properties Realty Trust, Inc. is an internally managed real estate investment trust that acquires, owns and manages primarily single-tenant properties that are net leased on a long-term basis to companies operating service-oriented or experience-based businesses. As of June 30, 2025, the Company's portfolio consisted of 2,190 freestanding net lease properties with a weighted average lease term of 14.3 years and a weighted average rent coverage ratio of 3.4x. In addition, as of June 30, 2025, the Company's portfolio was 99.6% leased to tenants operating 606 different concepts across 48 states.
